TY  - GEN
AU  - Mehra, Niven
AU  - Fizazi, Karim
AU  - de Bono, Johann S
AU  - Barthélémy, Philippe
AU  - Dorff, Tanya
AU  - Stirling, Adam
AU  - Machiels, Jean-Pascal
AU  - Bimbatti, Davide
AU  - Kilari, Deepak
AU  - Dumez, Herlinde
AU  - Buttigliero, Consuelo
AU  - van Oort, Inge M
AU  - Castro, Elena
AU  - Chen, Hsiang-Chun
AU  - Di Santo, Nicola
AU  - DeAnnuntis, Liza
AU  - Healy, Cynthia G
AU  - Scagliotti, Giorgio V
PY  - 2022
DO  - 10.1093/oncolo/oyac172
UR  - http://hdl.handle.net/20.500.12105/18570
AB  - The phase II TALAPRO-1 study (NCT03148795) demonstrated durable antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Here, we detail the safety profile of talazoparib. Men received talazoparib 1...
LA  - eng
KW  - BRCA
KW  - PARP inhibitor
KW  - castration-resistant prostatic cancer
KW  - talazoparib
KW  - Aged
KW  - Anemia
KW  - Antineoplastic Agents
KW  - DNA Damage
KW  - Humans
KW  - Male
KW  - Neutropenia
KW  - Phthalazines
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Prostatic Neoplasms, Castration-Resistant
TI  - Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
TY  - research article
ER  -